



Sydney Catalyst

# Strategic Plan

2016-2021

Approved by the Sydney Catalyst Governing Council  
February 2017 with minor updates June 2017

## Contents

Introduction & Background .....	2
Aim & Vision .....	3
Goals & Objectives.....	4
1. Develop and implement a comprehensive research program across the translational continuum – T1, T2 and T3 .....	5
2. Facilitate improved professional development, communication, and collaboration across the consortium .....	7
3. Build capacity in research, improve competitive advantage in securing other funds .....	8
4. Challenge the traditional, administrative and institutional barriers between clinicians and researchers to support a culture of embedding research and evidence in cancer healthcare.	
10	
Governance & Structure.....	11
Membership .....	13
Who .....	13
Why .....	13
Member Groups .....	14

## Introduction & Background


Sydney Catalyst is the translational cancer research centre of central Sydney and regional NSW. Established in July 2011 with a five year translational cancer research centre (TCRC) grant from the Cancer Institute NSW (CINSW), the consortium is a multi-disciplinary, multi-institutional endeavour that brings together approx. 600 clinician, researcher, and student members from a diverse range of member groups and institutions. **Our overall aim is to improve outcomes for people affected by cancer.** We do this by facilitating a comprehensive translational research program (see Diagram 1) that expedites the translation of new discoveries and clinical trials into routine treatment of patients.

### Our key achievements since July 2011 include;

- **Growth in membership** from 60 in 2011 to ~550 in mid-2016;
- Track record of high quality research outcomes – at least **\$222M in competitive funding and 1800 publications from key members;**
- **Portfolio of 80+ research projects and activities** that are led by us and/or otherwise attributable to the CINSW’s infrastructure funding support;
- **New and strengthened collaborations** across the translational spectrum and all clinical disciplines, especially GPs, allied health and nursing, surgeons, and regional clinicians;
- **Consumer engagement** via SAC, working groups, specific research projects;
- **Outstanding feedback received**, eg. 3 consecutive years of TCRC progress reporting received an excellent rating (5/5) against all criteria.
- We have **built capacity across the full spectrum of translational research**, with new competencies since inception including radiation oncology research, implementation science, imaging research, tumour immunity research.

In July 2016 Sydney Catalyst received a further five years of TCRC funding, providing essential infrastructure support for the program of work described within.

**Diagram 1: Translational Research**



## Aim & Vision

Sydney Catalyst aims to **improve outcomes for people affected by cancer.**

Our vision to achieve this is to develop and support a comprehensive multi-disciplinary, multi-institutional translational research program, which **as a whole is greater than the sum of its parts.**

We will bring together approx. 600 clinician, researcher, and student members from a diverse range of member groups and institutions. Our members are drawn from a broad range of disciplines in science, social science and medicine. From students to world-class research leaders, all Sydney Catalyst members are working individually and in collaboration toward our common aim and vision.

We will harness the talents and enthusiasm of our members through active engagement and be strong advocates for them, and translational cancer research in general, with a broad group of stakeholders. We will continue to build capacity in translational research through professional development, education, and support for translational researchers (especially early and mid-career researchers) and programs across the spectrum.

### Sydney Catalyst Core Competencies 2011-2021

5 years ago										
Prevention	Epidemiology/Health services research	Nursing and supportive care	Psychosocial	Medical Oncology	Radiation Oncology	Tissue Pathology and Diagnostic Oncology	Surgery	Clinical trials research	Palliative Care	
	Biostatistics	Big Linked Data			Cancer Genetics & Genomics					
Now										
Prevention	Epidemiology/Health services research	Nursing and supportive care	Psychosocial	Medical Oncology	Radiation Oncology	Tissue Pathology and Diagnostic Oncology	Surgery	Clinical trials research	Palliative Care	Implementation Science
Imaging	Biostatistics	Big Linked Data	Tumour Immunity		Cancer Genetics & Genomics					
5 years from now										
Prevention	Epidemiology/Health services research	Nursing and supportive care	Psychosocial	Medical Oncology	Radiation Oncology	Tissue Pathology and Diagnostic Oncology	Surgery	Clinical Trials Research	Palliative Care	Implementation Science
Imaging	Biostatistics	Big Linked Data	Tumour Immunity	High Throughput Biology	Cancer Genetics & Genomics	Cancer Metabolism	New Therapies	New Diagnostics	Integrated Research in Quality Care	Other New Competencies

## Goals & Objectives

An overview is provided below. Strategies for each of the four goals below are outlined in further detail in following pages. Members interested in viewing an extract of the application submitted to the CINSW that relates to these goals can email [sydneycatalyst@ctc.usyd.edu.au](mailto:sydneycatalyst@ctc.usyd.edu.au) for a copy.

1. <a href="#">Develop and implement a comprehensive research program across the translational continuum – T1, T2 and T3.</a>	2. <a href="#">Facilitate improved professional development, communication, and collaboration across the consortium.</a>	3. <a href="#">Build capacity in research, improve competitive advantage in securing other funds.</a>	4. <a href="#">Challenge the traditional, administrative and institutional barriers between clinicians and researchers to support a culture of embedding research and evidence in cancer healthcare.</a>
<p>1.1 Develop and lead world class translational research through 3 flagship programs.</p> <p>1.2 Support major translational research programs led by Sydney Catalyst members including CINSW schemes, other large state and federally funded programs (eg. MoST, SEPTA, ACRF Centenary Cancer Research Centre etc.).</p> <p>1.3 Continue to build core competencies across the full spectrum of translational research.</p> <p>1.4 Build capacity in evidence into practice and implementation research to ensure the timely and efficient translation of evidence into practice.</p> <p><b>Proposed KPIs include research outputs (grants, publications, funding leveraged); number, size and type of flagship and supported projects; new competencies realised.</b></p>	<p>2.1 Build an engaged and active community of Sydney Catalyst members through a formal communication and collaboration strategy.</p> <p>2.2 Support the professional development, education and training of our members through a unique program of translational research learning opportunities.</p> <p>2.3 Support early- and mid-career researchers to develop outstanding careers in translational cancer research.</p> <p>2.4 Seek and receive feedback from members, collaborators and other key stakeholders on the success of the program and opportunities for development and improvement.</p> <p><b>Proposed KPIs include number and type of professional development and collaborative activities; engagement of members with Sydney Catalyst, including proportion who participate in research and other activities, new collaborations between members.</b></p>	<p>3.1 Facilitate improved research governance and contractual arrangements across the consortium.</p> <p>3.2 Identify and engage key stakeholders, using a range of specific research projects, activities and communication strategies to build and maintain effective partnerships.</p> <p>3.3 Provide research support incl. concept development, tools to identify collaborators and resources, identification and incorporation of ‘translation into practice’ plans.</p> <p>3.4 Convene and facilitate themed Working Groups (WGs) to provide an important focus for advocacy of and expertise and activity in bench to bedside (T1/T2) research and evidence into practice (T2/T3) research.</p> <p><b>Proposed KPIs including number and type of research support provided, new ideas and concepts generated by WGs; engagement of key stakeholders.</b></p>	<p>4.1 Facilitate local and systems change through active engagement with clinicians and health professionals across a range of disciplines, plus clinical leads and health services and managers, using specific projects and activities as exemplars for facilitating the translation of clinical problems into research questions and answers.</p> <p>4.2 Develop and support initiatives to bind researchers and clinicians in their routine work.</p> <p>4.3 Assess and describe the extent to which research is and can be embedded in healthcare.</p> <p><b>Proposed KPIs include number and type of changes implemented, examples of new initiatives, development and use of metrics to evaluate research.</b></p>

## 1. Develop and implement a comprehensive research program across the translational continuum – T1, T2 and T3

1.1 Develop and lead world class translational research through 3 flagship programs.

- Flagship program 1 – EnRICH; Establish essential infrastructure to embed research and evidence in cancer healthcare, with lung cancer as an initial exemplar and plans to extend to other cancers later.
- Flagship program 2 – Pilot and Seed (P&S) Program; Support the development of new concepts and projects that align with the goals and research strategy, support and promote collaboration and have the capacity/potential to attract additional future funding from external sources.
- Flagship program 3 – Scholarships and Awards (Schols.) Program; Build capacity and support new researchers and clinicians who have the potential to develop significant careers in translational cancer research and whose research meets the overall goals and objectives of our program.

1.2 Support major translational research programs led by Sydney Catalyst members including CINSW schemes, other large state and federally funded programs (eg. MoST, ACRF Centenary Cancer Research Centre, NHMRC Program Grant at CTC etc.).

- An important subset of ‘Sydney Catalyst supported’ projects is those that receive funding from the CINSW as part of the TCRC exclusive funding schemes (ie. TPGs, REGs, RIGs, FRLs). We actively engage with applicants to improve competitive advantage and success. This includes providing advice and support to potential applicants, central review of all proposed applications to identify potential overlap and/or collaborative opportunities, and liaison with funding recipients to identify opportunities for collaboration. Our involvement in these specific projects and programs create opportunities for us to work more closely with funding recipients across a much broader range of work, with significant value to be added as a result of these relationships.
- Another important group of ‘Sydney Catalyst supported’ projects is those directly linked to our program and funded from other sources including competitive grants and sources, including;
  - Innovative clinical trials eg. the Cancer Molecular Screening and Therapeutics Program being led by David Thomas as part of Sydney Genomic Cancer Medicine Program.
  - ACRF-Centenary Cancer Research Centre in the Charles Perkins Centre, led by Phil Hogg, a new program with a focus on cancer thrombosis and tumour metabolism.
  - Federal gov. funded projects and programs, including the NHMRC CRE in Translational Breast Cancer Research led by Geoff Lindeman and involving John Simes as a CI (transBCR), the Cancer Australia Genomic Cancer Clinical Trials Initiative (GCCTI), the NHMRC Program Grant at the NHMRC Clinical Trials Centre;
- Identify and pursue partnerships with other academic research groups and industry (eg. international and national translational research centres and groups, collaborative clinical trials groups, commercialisation of new therapeutics and diagnostics etc.).

<p>1.3 Continue to build core competencies across the full spectrum of translational research.</p>	<ul style="list-style-type: none"> <li>• Leverage existing platforms and projects that have been established for scientific discovery to ensure translation of promising results into clinical trials.</li> <li>• Contribute to the establishment of Sydney Early Phase Trials Alliance (SEPTA), with consideration being given to a Sydney Catalyst led NIH consortium application (a long term goal).</li> </ul>
<p>1.4 Build capacity in implementation research to ensure the timely and efficient translation of evidence into practice.</p>	<ul style="list-style-type: none"> <li>• Areas of specific priority/opportunity may include cancer metabolism, new therapies, new diagnostic, and integrating research in quality care, although ongoing work to strengthen competency across other areas of research is also important.</li> <li>• Opportunities to build competencies include through flagship programs (esp. P&amp;S and Schols. programs) and supported programs, plus through professional development and education activities.</li> <li>• Encourage and facilitate the incorporation of translation into practice/implementation into all projects, especially clinical trials, as a mechanism to increase training in knowledge translation.</li> <li>• Support the translation of clinical problems into research questions and implementation projects eg. convening clinical forums, facilitating the use of clinical and other routine data for research.</li> <li>• Establish a curriculum around implementation as part of the broader Sydney Catalyst professional development program and/or in collaboration with others eg. CINSW convened Implementation CoP.</li> </ul>

*Proposed KPIs* – include research outputs (grants, publications, funding leveraged); number, size and type of flagship and supported projects; new competencies realised.

*Possible risks and challenges* - As a mature program with a large, disparate membership there is a need for balance between inclusion and focus in our research program. With finite resources we will continue to provide funding for 'bottom up' member led research through our P&S and Scholarship flagship programs, and more generic support through the other activities we have outlined within, that align with our overall goals and research strategy to ensure our efforts are focussed enough to make a difference but also inclusive of the interests and strengths of our broader membership.

## 2. Facilitate improved professional development, communication, and collaboration across the consortium

<p>2.1 Build an engaged and active community of Sydney Catalyst members through a formal communication and collaboration strategy.</p>	<ul style="list-style-type: none"> <li>• Website, monthly eNewsletter and social media strategy with articles and features to enable active engagement and participation of members and promotion of translational research, new opportunities, achievements and milestones.</li> <li>• Development and implementation of Sydney Catalyst led and promotion of other face to face events, to encourage cross fertilisation of members from different groups and disciplines.</li> </ul>
<p>2.2 Support the professional development, education and training of our members through a unique program of translational research learning opportunities.</p>	<ul style="list-style-type: none"> <li>• Including symposia, workshops, shared seminars, support for visiting national and international faculty etc.</li> <li>• Provide support to members participating in meetings, conferences and other professional development and education activities through a competitive Travel and Education Awards Program.</li> </ul>
<p>2.3 Support early- and mid-career researchers (ECRs and MCRs) to develop outstanding careers in translational cancer research.</p>	<ul style="list-style-type: none"> <li>• Facilitate opportunities for ECRs and MCRs in flagship programs and other Sydney Catalyst supported projects for eg. by using selection criteria to support ECR and MCRs, providing concept development support and workshops.</li> <li>• Provide opportunities for ECRs and MCRs to be involved in Sydney Catalyst governance and working groups eg.</li> <li>• Host an annual post-graduate student and ECR symposium to provide a specific opportunity for ECRs to present their work to a wide audience.</li> </ul>
<p>2.4 Seek and receive feedback from members, collaborators and other key stakeholders on the success of the program and opportunities for development and improvement.</p>	<ul style="list-style-type: none"> <li>• Use formal and informal processes to evaluate the program, both with respect to the specific research projects and activities that we fund and support, as well as to better understand our membership and their needs.</li> <li>• We will continue to examine, describe and evaluate our program through member and stakeholder surveys, external reviews and other evaluation methods eg working independently and in collaboration with others incl. CINSW to further develop indicators and measures of our progress and success.</li> <li>• Convene a standing External Review Panel and undertake a biennial review meeting.</li> </ul>

*Proposed KPIs* - include number and type of professional development and collaborative activities; engagement of members with Sydney Catalyst, including proportion who participate in research and other activities, new collaborations between members.

*Potential risks and challenges* - The size and breadth of our membership can be a challenge to maintaining active and meaningful engagement, but some of the strategies we have to deal with this include seeking good representation of our membership in our governance structure and flagship programs, a strong focus on activities to enhance communication and collaboration, identification of 'key' members for involvement in specific activities etc.

### 3. Build capacity in research, improve competitive advantage in securing other funds

3.1 Facilitate improved research governance and contractual arrangements across the consortium.

- Explore how a collaborative approach to biobanking, including governance and contractual arrangements, might be managed.
- Use existing projects and flagship programs eg. EnRICH to streamline processes and share learnings with members to facilitate improved processes across the consortium.

3.2 Identify and engage key stakeholders, using a range of specific research projects, activities and communication strategies to build and maintain effective partnerships.

- Notable examples of existing links include Sydney Research and Sydney Health Partners, Cancer Research UK (A Biankin and S Kaye), Harvard Catalyst (E Guinan and V De Gruttloa), NCIC CTG (L Seymour) etc. but to date these links haven't been applied to any specific projects or activities.
- Government, industry, academia including other TCRCs are all potential stakeholders/collaborators, but need to think about how to approach these in a way that is useful.
- National CREs might provide useful examples for governance and centre administration. Similarly, member based not-for-profits might inform medium-long term sustainability.
- Build and strengthen our collective narrative to share with stakeholders and the community (eg. via social media, website, other marketing initiatives and collateral).
- Leverage existing reporting systems to facilitate the collection and reporting of information about the entire Sydney Catalyst program of research for communication with stakeholders including CINSW for annual progress reporting.

3.3 Provide research support incl. concept development, tools to identify collaborators and resources, identification and incorporation of 'translation into practice' plans.

- Advice and support for concept and research development; centrally we have expertise in concept and project development and management (research design and operations, project management, biostatistics, budget development and management etc.). We also have excellent access to a larger group of senior investigators for peer-review;
- Access to unique web-based resources eg. Find a Resource, Find a Collaborator etc;
- Participation in a Sydney Catalyst led or supported concept development workshops;
- Formal identification of Sydney Catalyst as a collaborating partner;
- Identification and incorporation of 'translation into practice' plans in clinical trials; we will use our expertise and capacity in knowledge translation and implementation to work with clinical trial investigators and groups to assist them to formally acknowledge and embed translation into practice in their research. We will do this through our close relationship with

3.4 Convene and facilitate themed Working Groups (WGs) to provide an important focus for advocacy for and expertise and activity in bench to bedside (T1/T2) research and evidence into practice (T2/T3) research.

- the NHMRC Clinical Trials Centre and the national cancer cooperative trials groups (including AGITG, ANZGOG, ANZUP, ALTG, COGNO, PoCoG and PC4 - all are collaborating partner groups).
- Highlighting the work of our members and their research achievements; we have created an actively engaged community of dedicated cancer researchers, clinicians and students collectively contributing to a substantial body of cancer research across the translational continuum. The Sydney Catalyst community is an important mechanism for local dissemination, with members being given opportunities to share their research through our website, eNewsletter, and a range of virtual resources and face to face member events (eg. scientific symposia, education dinner series events etc.). Our strong linkages with local health districts and cancer care services encourages the uptake of new research findings amongst clinicians.
  - Facilitate and convene expert themed working groups to generate new ideas, build capacity and advocate for the interests of members in their respective areas of expertise.

*Proposed KPIs* – include number and type of research support provided, new ideas and concepts generated by WGs; engagement of key stakeholders

*Proposed risks and challenges* - While the CINSW TCRC program has been an important impetus for the establishment and growth of Sydney Catalyst to date, we propose to further develop the program over the next five years, such that it may grow to be independent of CINSW TCRC funding. Review of different models of governance, funding and sustainability will be an important consideration, as will be careful reflection of the overall benefit of the centre to members and its value as a whole, which should be greater than the sum of its parts.

#### 4. Challenge the traditional, administrative and institutional barriers between clinicians and researchers to support a culture of embedding research and evidence in cancer healthcare.

4.1 Facilitate local and systems change through active engagement with clinicians and health professionals across a range of disciplines, using specific projects and activities as exemplars for facilitating the translation of clinical problems into research questions and answers.

- Flagship programs, especially EnRICH, will provide an important opportunity for this, while additional opportunities to facilitate the translation of clinical problems into research questions and answers will be further explored.
- The themed working groups also provide an important mechanism for clinicians and researchers to work together to identify problems and solutions.

4.2 Develop and support initiatives to bind researchers and clinicians in their routine work.


- Cancer grand rounds, involvement of researchers in MDTs, clinical placements for researchers, laboratory placements for clinicians etc.

4.3 Assess and describe the extent to which research is and can be embedded in healthcare.

- Define metrics to assess and describe the extent to which research is embedded in healthcare and if feasible, facilitate the routine inclusion and reporting of these metrics across Sydney Catalyst clinical sites.
- The proposed metrics include, but are not limited to;
  - Participation in clinical research: Numbers (%) of patients in trials / clinical research
  - Number and type of clinical trials undertaken – how to define? Type of trials vs other types of clinical research, industry vs academic, drug/medical vs others. Use ANZCTR?
  - Timeliness and efficiency of clinical trials research ; Tony Penna is collecting metrics
  - Quality of research
    - Type of research design (eg: controlled or not; clinical vs surrogate outcomes)
    - Quality of trial conduct and data
  - Impact of research on changing practice and policy in health sector
  - Culture of embedded research in health care
  - Generic consent for research participation
  - Amount of protected time for research
  - Incorporation of research in clinical activities eg MDTs
  - Use of research to inform health policy
  - High quality clinical audit activities particularly
  - Clinical quality registry activity
  - Comparative effectiveness studies to define / extend evidence

*Proposed KPIs* - include number and type of changes implemented, examples of new initiatives, development and use of metrics to evaluate research.

## Governance & Structure



**Governing Council (GC);** Key leadership group, responsible for developing and overseeing the overall aims, objectives and strategic plan for Sydney Catalyst. GC meets every 2 months and members include;

- our Director, Professor John Simes;
- our 6 Senior Research and Clinical Leaders; Professors Michael Boyer (GC Chair), Phyllis Butow, Philip Hogg, David Thomas, Mathew Vadas, and Jane Young;
- and from July 2016 two additional representatives; Philip Beale (Medical Oncologist and Cancer Services Director, SLHD) and Karen Briscoe (Medical Oncologist, North Coast Cancer Institute, Coffs Harbour).

**External Review Panel;** Following two successful external reviews convened in 2013 and 2015, we will establish a standing external review panel, with twice yearly meetings via tele/video-conference planned, in addition to periodic site visits (eg. 1-2 times during the course of the TCRC grant). Professor Derek Raghavan has been identified to lead this group and process, with a panel of additional national and international members for each review period (defined around site visits).

**Scientific Advisory Committee (SAC);** Advises GC on all scientific matters and helps set our research, education and training strategy. SAC meets 3 times a year in a combined meeting with GC, is chaired by Professor Phyllis Butow, and members are recognised for their scientific and other experiences relevant to advising scientific and research directions of Sydney Catalyst and membership. Related groups include;

- **Themed Working Groups (WGs);** We currently have two themed working groups, the bench to bedside (T1/T2) WG and the evidence into practice (T2/T3) WG, both of which include members with appropriate expertise and representative of the Sydney Catalyst membership. **The WGs provide an important focus for expertise and activity.**
- **Sydney Catalyst Funding and Award Review Panels;** For each annual round of P&S and Schols. funding, we will identify a review panel comprised of 5-8 Sydney Catalyst members, led by SAC members (Kate White and Philip Hogg for P&S and Peter Grimison for Schols.), who will be responsible for overseeing and inputting into the application process specifically through scoring and ranking applications to make funding recommendations to GC & SAC. This is an important mechanism for us to seek additional expert advice and engage a larger group of members in determining the projects that are supported through our flagship programs.

**Executive Committee and Operations Team;** The day to day operations of the **Sydney Catalyst** program is the responsibility of the Operations Team (comprised of the Director, Deputy Director, Research Manager and other senior staff), which meets at least weekly to plan and execute a range of activities under the guidance and direction of the Executive Committee (comprised of the Director, Deputy Director, Chairs of GC and SAC, and the Research Manager), which meets every 2-4 weeks and reports directly to the GC.

**Sydney Catalyst Members;** Active engagement of our members is also an important enabler in our success. Our members are significantly involved in our research, professional development and education, communication and collaboration activities. The breadth, depth, expertise and commitment of our members is exemplified in the detailed roles of our 600 members. Building an engaged and active community of Sydney Catalyst members has been an important way for us to facilitate collaboration between clinical and research disciplines, leading to hubs of research and clinical services excellence. We have also developed productive links with a wide range of national and international collaborators, with some notable examples including the USYD Cancer Research Network (CRN), Sydney Research and Sydney Health Partners (both of which include other TCRCs), Cancer Research UK (ABiankin, SKaye), Harvard Catalyst (EGuinan, VDe Gruttola), NCIC CTG (LSeymour).



## Membership

### Who

Membership is open to clinicians, researchers and students whose primary area of interest is cancer treatment, research or education.

Members usually belong to one of our [Member Groups](#) but individual membership applications may also be considered. Please [contact us](#) to discuss these.

### Why

Our goal is to improve health outcomes for people affected by cancer through a rigorous translational cancer research program. Our members are critical to this aim.

Members have exclusive access to **Sydney Catalyst** offerings including:

- eligibility to apply for **Sydney Catalyst** funding through the [Sydney Catalyst Scholarships and Awards Scheme](#) and the [Sydney Catalyst Pilot and Seed Funding Program](#).
- eligibility to apply for [Cancer Institute NSW funds](#) via those schemes that require membership and/or support of a Translational Cancer Research Centre.
- access to exclusive **Sydney Catalyst** [education and networking events](#), including our Education Dinner Series, webinars and symposia.
- access to a range of online resources and tools through the **Sydney Catalyst** [e-Newsletter](#) and website, including our unique [Research Marketplace](#).
- access to [Research Support](#), which may include help to create new or strengthen existing collaborations, advice and/or input into concept and/or protocol development and support for funding applications.
- the opportunity to participate in a range of themed working groups and committees and contribute actively to the **Sydney Catalyst** program.

## Member Groups

Sydney Catalyst has formally identified a number of academic and clinical groups as institutional members of our endeavours. The current member groups are listed below. Changes and/or amendments must be approved by Governing Council.

Asbestos Diseases Research Institute (ADRI)
ANZAC Research Institute
- Dendritic Cell Research
Bathurst Base Hospital
Cancer Researchers, University of Sydney main campus
- Cancer Research Network
- NHMRC Clinical Trials Centre (CTC)
- The Cancer Nursing Research Unit (based at SCC)
- Centre for Medical Psychology & Evidence-based Decision-making (CeMPED)
Centenary Institute
Concord Repatriation General Hospital
Dubbo Base Hospital
Melanoma Institute Australia
North Coast Cancer Institute, Coffs Harbour Base Hospital
Orange Health Service Hospital
Royal Prince Alfred Hospital
- Institute of Haematology
- Institute of Academic Surgery including Surgical Outcomes Research Centre (SOuRCE)
- Department of Radiation Oncology
- Tissue Pathology & Diagnostic Oncology
- RPA Neuropathology
St. Vincent's Hospital includes Sacred Heart Hospice, Cunningham Centre for Palliative Care Research
- Sacred Heart Hospice
- Cunningham Centre for Palliative Care Research
Chris O'Brien Lifehouse
Garvan Institute includes The Kinghorn Cancer Centre
Wagga Wagga Base Hospital
Collaborating Partner Groups of Sydney Catalyst include: Australasian Gastro-Intestinal Trials Group (AGITG); Australasian Lung Cancer Trials Group (ALTG); The Australian New Zealand Gynaecological Oncology Group (ANZGOG); Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); The Cooperative Trials Group for Neuro-Oncology (COGNO);



The Primary Care Collaborative Cancer Clinical Trials Group (PC4);  
The Psycho-Oncology Co-Operative Research Group (PoCoG);  
Woolcock Lung Cancer Centre and Network.